400 related articles for article (PubMed ID: 21849527)
21. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.
Kim YD; Park CH; Kim HS; Choi SK; Rew JS; Kim DY; Koh YS; Jeung KW; Lee KH; Lee JS; Juhng SW; Lee JH
J Gastroenterol Hepatol; 2008 Jan; 23(1):110-8. PubMed ID: 18171349
[TBL] [Abstract][Full Text] [Related]
22. Components of the canonical and non-canonical Wnt pathways are not mis-expressed in pituitary tumors.
Colli LM; Saggioro F; Serafini LN; Camargo RC; Machado HR; Moreira AC; Antonini SR; de Castro M
PLoS One; 2013; 8(4):e62424. PubMed ID: 23638078
[TBL] [Abstract][Full Text] [Related]
23. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
[TBL] [Abstract][Full Text] [Related]
24. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
[TBL] [Abstract][Full Text] [Related]
25. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
Wu R; Zhai Y; Fearon ER; Cho KR
Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
[TBL] [Abstract][Full Text] [Related]
26. Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability.
Thorstensen L; Lind GE; Løvig T; Diep CB; Meling GI; Rognum TO; Lothe RA
Neoplasia; 2005 Feb; 7(2):99-108. PubMed ID: 15802015
[TBL] [Abstract][Full Text] [Related]
27. Redundant expression of canonical Wnt ligands in human breast cancer cell lines.
Benhaj K; Akcali KC; Ozturk M
Oncol Rep; 2006 Mar; 15(3):701-7. PubMed ID: 16465433
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of CTNNB1 in adrenocortical carcinomas: Identification of novel mutations and correlation to survival.
Maharjan R; Backman S; Åkerström T; Hellman P; Björklund P
Sci Rep; 2018 Jun; 8(1):8610. PubMed ID: 29872083
[TBL] [Abstract][Full Text] [Related]
29. An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET).
Rogers HA; Miller S; Lowe J; Brundler MA; Coyle B; Grundy RG
Br J Cancer; 2009 Apr; 100(8):1292-302. PubMed ID: 19293793
[TBL] [Abstract][Full Text] [Related]
30. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
[TBL] [Abstract][Full Text] [Related]
31. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
[TBL] [Abstract][Full Text] [Related]
32. Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas.
Hölsken A; Kreutzer J; Hofmann BM; Hans V; Oppel F; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Brain Pathol; 2009 Jul; 19(3):357-64. PubMed ID: 18540944
[TBL] [Abstract][Full Text] [Related]
33. Wnt signaling pathway analysis in renal cell carcinoma in young patients.
Bruder E; Moch H; Ehrlich D; Leuschner I; Harms D; Argani P; Briner J; Graf N; Selle B; Rufle A; Paulussen M; Koesters R
Mod Pathol; 2007 Dec; 20(12):1217-29. PubMed ID: 17873895
[TBL] [Abstract][Full Text] [Related]
34. Wnt signaling and telomerase activation of hepatoblastoma: correlation with chemosensitivity and surgical resectability.
Ueda Y; Hiyama E; Kamimatsuse A; Kamei N; Ogura K; Sueda T
J Pediatr Surg; 2011 Dec; 46(12):2221-7. PubMed ID: 22152854
[TBL] [Abstract][Full Text] [Related]
35. Alteration in the Wnt/β-catenin signaling pathway in gastric neoplasias of fundic gland (chief cell predominant) type.
Hidaka Y; Mitomi H; Saito T; Takahashi M; Lee SY; Matsumoto K; Yao T; Watanabe S
Hum Pathol; 2013 Nov; 44(11):2438-48. PubMed ID: 24011952
[TBL] [Abstract][Full Text] [Related]
36. Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors.
Kim JT; Li J; Jang ER; Gulhati P; Rychahou PG; Napier DL; Wang C; Weiss HL; Lee EY; Anthony L; Townsend CM; Liu C; Evers BM
Carcinogenesis; 2013 May; 34(5):953-61. PubMed ID: 23354304
[TBL] [Abstract][Full Text] [Related]
37. CTNNB1 Knockdown Inhibits Cell Proliferation and Aldosterone Secretion Through Inhibiting Wnt/β-Catenin Signaling in H295R Cells.
Zhou T; Luo P; Wang L; Yang S; Qin S; Wei Z; Liu J
Technol Cancer Res Treat; 2020; 19():1533033820979685. PubMed ID: 33287648
[TBL] [Abstract][Full Text] [Related]
38. Role of Wnt pathway in medulloblastoma oncogenesis.
Yokota N; Nishizawa S; Ohta S; Date H; Sugimura H; Namba H; Maekawa M
Int J Cancer; 2002 Sep; 101(2):198-201. PubMed ID: 12209999
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
[TBL] [Abstract][Full Text] [Related]
40. Mutations in components of the Wnt signaling pathway in gastric cancer.
Pan KF; Liu WG; Zhang L; You WC; Lu YY
World J Gastroenterol; 2008 Mar; 14(10):1570-4. PubMed ID: 18330950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
